Nom du produit:2-Aminonicotinaldehyde

IUPAC Name:2-aminopyridine-3-carbaldehyde

CAS:7521-41-7
Formule moléculaire:C6H6N2O
Pureté:98%
Numéro de catalogue:CM103325
Poids moléculaire:122.13

Unité d'emballage Stock disponible Prix($) Quantité
CM103325-25g in stock ȖŪ
CM103325-100g in stock ƐƐŸ
CM103325-500g in stock ƚŸȯǫ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:7521-41-7
Formule moléculaire:C6H6N2O
Point de fusion:-
Code SMILES:O=CC1=C(N)N=CC=C1
Densité:
Numéro de catalogue:CM103325
Poids moléculaire:122.13
Point d'ébullition:
N° Mdl:MFCD01830382
Stockage:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.